Home Companies Catalysts Deep Dives
LUMAKRAS sotorasib APPROVED
Drug Profile
ModalitySmall molecule
RouteOral
Therapy AreaOncology
Launch2021-05-28
Peak Sales Est$500M
Formulations[{"id":"lumakras-oral","doses":"960mg (8 tablets) QD or 240mg QD (CodeBreaK 200)","route":"Oral","se
Companies
AMGN (ORIGINATOR)100%
Mechanism: KRAS G12C inhibitor
Expert: Irreversible, selective small molecule inhibitor of KRAS G12C. Traps KRAS G12C in inactive GDP-bound state. Oral QD.
Everyday: Locks the KRAS G12C protein in its "off" position, preventing it from sending growth signals to cancer cells. KRAS was considered "undruggable" for 40 years.
Targets: ["KRAS"]
Revenue History
PeriodRevenue ($M)
2024$350M
2025$363M
Programs (1)
IndicationStageKey StudyRegional Status
KRAS G12C NSCLC 2L+APPROVEDCodeBreaK 200[{"stage":"APPROVED","region":"US","approval_date":"2021-05-28"}]
Notes
Modest growth. Competitive with Mirati adagrasib. CodeBreaK 200 showed lower dose (240mg) comparable efficacy — improved convenience. Not a major growth driver.
Data from Supabase · Updated 2026-03-24